Use of a Virtual Reality Headset During Prostate Biopsy Under Local Anesthesia to Improve the Patient's Experience
Use of a Virtual Reality Visor (REALICA®) as an Supplementary Tool to Local Anesthesia in Patients Undergoing Prostate Biopsy: A Randomized Clinical Trial
This is a post-market clinical investigation evaluating the effect of immersive virtual reality (VR) as an adjunct to standard local anesthesia during transperineal prostate biopsy.
Transperineal prostate biopsy under local anesthesia is commonly associated with patient anxiety, procedural discomfort, and vasovagal reactions, which may negatively impact patient experience and procedural tolerability. Non-pharmacological distraction techniques such as immersive VR have shown potential to reduce perceived pain and anxiety during short, invasive medical procedures by modulating cognitive attention and emotional response.
This study investigates whether the use of an immersive VR headset, added to standard local anesthesia, can reduce peri-procedural anxiety and pain compared to standard care alone. The intervention is designed to provide continuous audiovisual immersive distraction starting shortly before the procedure and continuing throughout the biopsy, without altering standard clinical workflow or increasing procedural invasiveness.
This is a randomized, controlled, parallel-group, 1:1 superiority trial with a single-blind (assessor-blinded) design. Participants undergoing transperineal prostate biopsy under local anesthesia will be randomly assigned to one of two groups: standard local anesthesia alone (control arm) or standard local anesthesia plus immersive VR (experimental arm).
The primary objective is to evaluate whether immersive VR reduces peri-procedural anxiety and pain compared with standard local anesthesia alone. Secondary objectives may include evaluation of patient satisfaction, tolerability of the VR intervention, and incidence of vasovagal reactions or procedural interruptions.
The study aims to generate evidence on the feasibility and clinical benefit of integrating immersive VR as a non-pharmacological supportive tool in urological diagnostic procedures.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Italy
-
Milan, Italy, Itália, 20132
- IRCCS Ospedale San Raffaele
-
Contato:
- Simone Scuderi
- Número de telefone: +39 02 2643 6922
- E-mail: scuderi.simone@hsr.it
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- The participant provides written informed consent for the trial
- Male participants who are at least 18 years of age on the day of signing informed consent
- Men undergoing transperineal prostate biopsy under local anesthesia
Exclusion Criteria:
- Visual or hearing impairment that would prevent effective use of the virtual reality device
- History of epilepsy or seizure disorders
- Severe motion sickness or known susceptibility to cybersickness
- Severe psychiatric disorders that, in the investigator's judgment, could interfere with study participation or outcome assessment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Arm A (Control)- Transperineal Prostate Biopsy under Local Anesthesia
Participants undergo transperineal prostate biopsy performed under standard clinical practice using local anesthesia.
Local anesthetic is administered according to institutional protocol prior to the procedure.
No additional interventions or supportive devices are used in this arm.
Patients receive routine peri-procedural monitoring and care as per standard of care.
|
Transperineal prostate biopsy performed under standard clinical practice using local anesthesia administered according to institutional protocol.
No additional supportive or experimental interventions are applied.
|
|
Experimental: Arm B (Experimental)- Local anesthesia + immersive VR headset
Participants undergo transperineal prostate biopsy performed under standard clinical practice using local anesthesia, with the addition of an immersive virtual reality (VR) headset as a supportive intervention.
The VR device is applied approximately 3-5 minutes before the start of the procedure and is worn continuously throughout the biopsy.
The VR experience is used as a non-pharmacological distraction tool intended to reduce peri-procedural anxiety and pain.
|
Transperineal prostate biopsy performed under standard local anesthesia with the addition of an immersive virtual reality (VR) headset used as a non-pharmacological distraction tool.
The VR device is applied approximately 3-5 minutes before the start of the procedure and worn continuously throughout the biopsy.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Procedural Pain Intensity
Prazo: Immediately after completion of the biopsy procedure
|
Pain will be assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain)
|
Immediately after completion of the biopsy procedure
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Procedural anxiety
Prazo: Immediately post-procedure
|
Assessed using the State-Trait Anxiety Inventory Form Y-1 (STAI-Y1).
The STAI-Y1 total score ranges from 20 to 80, with higher scores indicating greater anxiety
|
Immediately post-procedure
|
|
Decision regret
Prazo: 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the validated Decision Regret Scale (DRS).
The Decision Regret Scale is a 5-item questionnaire assessing regret following a healthcare decision.
Scores range from 0 to 100, with higher scores indicating greater decision regret.
|
1 month (Day 30 ± 5 days) after the procedure
|
|
Urinary incontinence
Prazo: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF).
Total scores range from 0 to 21, with higher scores indicating greater severity of urinary incontinence.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Lower urinary tract symptoms
Prazo: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the International Prostate Symptom Score (IPSS).
Total scores range from 0 to 35, with higher scores indicating greater severity of lower urinary tract symptoms.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Sexual function
Prazo: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the International Index of Erectile Function (IIEF).
The IIEF is a validated 15-item questionnaire assessing male sexual function.
Total scores range from 5 to 75, with higher scores indicating better sexual function.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Health-related quality of life
Prazo: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ).
The EORTC QLQ is a validated questionnaire assessing health-related quality of life.
Scores are transformed into a 0 to 100 scale.
For functional scales and global health status, higher scores indicate better quality of life, whereas for symptom scales, higher scores indicate greater symptom burden.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Depressive symptoms
Prazo: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the Patient Health Questionnaire-9 (PHQ-9).
The PHQ-9 is a 9-item questionnaire assessing depressive symptoms.
Total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Post-procedural complications
Prazo: During the procedure and up to 30 days after the procedure
|
Collection of all reported complications related to the biopsy procedure, including vasovagal reactions and other adverse events.
|
During the procedure and up to 30 days after the procedure
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- VR-biopsy
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .